Dolors Colomer

Grupo de investigación

Terapias experimentales en neoplasias linfoides Group leader (R4)

dcolomer@clinic.cat 0000-0001-7486-8484

Síguelo/a en:

El perfil Researchgate de Dolors . Este enlace se abre en una nueva pestaña.

Publicaciones destacadas

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

Autores:
Gimenez, Neus; Tripathi, Rupal; Giro, Ariadna; Rosich, Laia; Lopez-Guerra, Monica;

(...)

Perez-Galan, Patricia; Delgado, Julio; Campo, Elias; Farres, Judith; Colomer, Dolors.

Referencia: Scientific Reports 2020.
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells

Autores:
Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Fuentes, Patricia; Roldan, Jocabed; Gonzalez-Farre, Blanca;

(...)

Lopez-Guillermo, Armando; Puente, Xose S; Campo, Elias; Toribio, Maria L; Colomer, Dolors.

Referencia: Oncogene 2020.
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

Autores:
Gimenez, Neus; Schulz, Ralph; Higashi, Morihiro; Aymerich, Marta; Villamor, Neus;

(...)

Lopez-Guerra, Monica; Campo, Elias; Rosich, Laia; Seiffert, Martina; Colomer, Dolors.

Referencia: Leukemia 2020.
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy

Autores:
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M;

(...)

Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D .

Referencia: Journal Of Experimental & Clinical Cancer Research 2019.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Autores:
Lee-Verges, Eriong; Hanna, Bola S; Yazdanparast, Haniyeh; Rodriguez, Vanina; Leonor Rodriguez, Marta;

(...)

Perez-Galan, Patricia; Lopez-Guerra, Monica; Campo, Elias; Seiffert, Martina; Colomer, Dolors.

Referencia: International Journal Of Cancer 2019.
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues

Autores:
Hanna B; Roessner P; Yazdanparast H; Colomer D; Campo E;

(...)

Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M.

Referencia: Leukemia 2019.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Autores:
Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

(...)

Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

Referencia: Haematologica 2017.
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Autores:
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M;

(...)

Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA .

Referencia: Clinical Cancer Research 2017.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Autores:
Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

(...)

Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

Referencia: Clinical Cancer Research 2017.
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.

Autores:
Tripathi R; Lee-Verges E; Higashi M; Gimenez N; Rosich L;

Lopez-Guerra M; Colomer D .

Referencia: Expert Opinion On Drug Discovery 2017.

Proyectos destacados

Transpyrenean network of advanced therapies in non-Hodgkin lymphoma - THERAVLINFO (INTERREG-POCTEFA program EFA123/1)

Investigador/a principal: Dolors Colomer Pujol, Patricia Pérez Galán

Duración: 01/01/2024

Web: http://theravlinfo.eu/
Nuevos modelos para el estudio de las alteraciones genéticas recurrentes y resistencia a fármacos en la leucemia linfática crónica

Investigador/a principal: Dolors Colomer Pujol

Financiador: MINECO

Código: RTI2018-094584-B-I00

Duración: 01/08/2019 - 31/12/2021
Cross border network of personalized immunotherapies in non-Hodgkin lymphoma.

Investigador/a principal: Patricia Pérez Galán

Financiador: EU-INTERRREG-POCTEFA (Programa financiador competitivo)

Código: EFA281/16/IMLINFO

Duración: 01/01/2018 - 31/12/2020
Dianes terapèutiques i noves tècniques diagnostiques en neoplasies linfoides.

Investigador/a principal: Dolors Colomer Pujol

Financiador: AGAUR (Programa financiador competitivo)

Código: 2017_SGR_1009

Duración: 01/01/2018 - 31/12/2019
neoplasias hematologicas- patologia linfoide

Investigador/a principal: Dolors Colomer Pujol

Financiador: CIBER de enfermedades oncologicas (CIBERONC) (Programa financiador competitivo)

Código: CB16/12/00334.

Duración: 01/01/2017

Dolors Colomer

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Transpyrenean network of advanced therapies in non-Hodgkin lymphoma - THERAVLINFO (INTERREG-POCTEFA program EFA123/1)

Nuevos modelos para el estudio de las alteraciones genéticas recurrentes y resistencia a fármacos en la leucemia linfática crónica

Cross border network of personalized immunotherapies in non-Hodgkin lymphoma.

Dianes terapèutiques i noves tècniques diagnostiques en neoplasies linfoides.

neoplasias hematologicas- patologia linfoide

Suscríbete a la Newsletter del Clínic